exhibit {num} 
n w bio announced a registered direct offering of ${num} million 
with new institutional investors 
bethesda , md . , july {num} {num} – northwest biotherapeutics ( nasdaq : nwbo ) ( nw bio ) , a biotechnology company developing dcvax® personalized immune therapies for solid tumor cancers , today announced that it has entered into definitive agreements with two new institutional investors for a registered direct offering with gross proceeds of ${num} million . 
the company will sell to the investors approximately {num} million shares of common stock at a purchase price of $ . {num} per share resulting in gross proceeds to the company of ${num} million . the investors will also receive warrants to purchase up to approximately {num} million shares of common stock with an exercise price of $ . {num} per share and an exercise period of 5 years . 
chardan capital markets , llc acted as the exclusive placement agent for the transaction . 
the placement is expected to close on or about july {num} {num} subject to satisfaction of customary closing conditions . 
the securities described above are being offered pursuant to a shelf registration statement ( file no . {num}-{num} ) , which was declared effective by the united states securities and exchange commission ( " sec " ) on december {num} {num} this press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein , nor shall there be any sale of these securities in any state or jurisdiction in which such offer , solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction . when filed with the sec , copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the sec's website at http : / / www . sec . gov . 
about northwest biotherapeutics 
northwest biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments , without toxicities of the kind associated with chemotherapies , and on a cost-effective basis , in both the united states and europe . the company has a broad platform technology for dcvax dendritic cell-based vaccines . the company's lead program is a {num}-patient phase iii trial in newly diagnosed glioblastoma multiforme ( gbm ) , which is on a partial clinical hold in regard to new screening of patients . gbm is the most aggressive and lethal form of brain cancer , and is an " orphan disease . " the company is under way with a {num}-patient phase i / ii trial with dcvax-direct for all types of inoperable solid tumor cancers . it has completed enrollment in the phase i portion of the trial . the company previously conducted a phase i / ii trial with dcvax-l for metastatic ovarian cancer together with the university of pennsylvania . the company previously received clearance from the fda for a {num}-patient phase iii trial in prostate cancer . in germany , the company has received approval of a 5-year hospital exemption for the treatment of all gliomas ( primary brain cancers ) outside the clinical trial . 
disclaimer 
statements made in this news release that are not historical facts , including statements concerning future treatment of patients using dcvax and future clinical trials , are forward-looking statements within the meaning of the private securities litigation reform act of {num} words such as " expect , " " believe , " " intend , " " design , " " plan , " " continue , " " may , " " will , " " anticipate , " and similar expressions are intended to identify forward-looking statements . actual results may differ materially from those projected in any forward-looking statement . specifically , there are a number of important factors that could cause actual results to differ materially from those anticipated , such as risks and uncertainties related to the actions and decisions of nasdaq and cognate , the company's ongoing ability to raise additional capital , risks related to the company's ability to enroll patients in its clinical trials and complete the trials on a timely basis , uncertainties about the clinical trials process , uncertainties about the timely performance of third parties , risks related to whether the company's products will demonstrate safety and efficacy , risks related to the company's and cognate's abilities to carry out the intended manufacturing and expansions contemplated in the cognate agreements , risks related to the company's ability to carry out the hospital exemption program and risks related to possible reimbursement and pricing . additional information on these and other factors , including risk factors , which could affect the company's results , is included in its securities and exchange commission ( " sec " ) filings . finally , there may be other factors not mentioned above or included in the company's sec filings that may cause actual results to differ materially from those projected in any forward-looking statement . you should not place undue reliance on any forward-looking statements . the company assumes no obligation to update any forward-looking statements as a result of new information , future events or developments , except as required by securities laws . 
contact 
les goldman 
{num}-{num}-{num} 
lgoldman@nwbio . com 
